What is the recommended dosing, dose adjustments, monitoring schedule, and contraindications for niraparib (a PARP inhibitor) as maintenance therapy in adult patients with ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum‑based chemotherapy, including considerations for patients weighing less than 77 kg or with baseline platelet counts below 150 × 10⁹/L?

Niraparib Dosing and Management

For first-line maintenance therapy in ovarian cancer, start niraparib at 200 mg daily if baseline body weight is <77 kg OR baseline platelet count is <150,000/μL; otherwise start at 300 mg daily 1, 2.

Recommended Dosing Strategy

Initial Dose Selection (Individualized Starting Dose - ISD)

• 200 mg daily (2 × 100-mg capsules): Patients with baseline body weight <77 kg OR baseline platelet count <150 × 10⁹/L
• 300 mg daily (3 × 100-mg capsules): Patients with baseline body weight ≥77 kg AND baseline platelet count ≥150 × 10⁹/L

This individualized approach from the PRIMA trial 1 has been prospectively validated and demonstrates similar efficacy with significantly improved safety compared to fixed 300 mg dosing 3.

Timing of Initiation

• Begin within 12 weeks of the first day of the last cycle of platinum-based chemotherapy 1
• Ensure adequate baseline platelet recovery before starting (≥100,000/μL minimum in real-world practice) 4
• Median initiation time is approximately 4 weeks post-chemotherapy 4

Dose Modifications

For Thrombocytopenia (Most Common Toxicity)

Onset typically occurs within the first month of treatment 5, 4:

• Grade 1-2 (75,000-150,000/μL): Continue current dose with weekly monitoring
• Grade 3 (25,000-75,000/μL):
  • Interrupt treatment
  • Monitor platelets weekly
  • Resume at reduced dose (reduce by 100 mg) when platelets ≥100,000/μL
• Grade 4 (<25,000/μL):
  • Interrupt treatment immediately
  • Monitor platelets twice weekly
  • Resume at reduced dose when platelets ≥100,000/μL

Critical point: Most thrombocytopenia resolves within approximately 2 weeks with dose interruption 5. The RADAR strategy demonstrates that patients starting at 200 mg have significantly lower rates of grade ≥3 thrombocytopenia (4.2% vs 41.7% with 300 mg) 6.

Dose Escalation Consideration

For patients starting at 200 mg: If no thrombocytopenia, severe neutropenia, or anemia occurs within the first 3 cycles, consider escalating to 300 mg at cycle 4 6.

Monitoring Schedule

Platelet Count Monitoring (Priority)

• Baseline: Within 1 week before starting
• First month: Weekly (when 67% of dose reductions occur) 7
• Months 2-3: Every 2 weeks
• After month 3: Monthly or as clinically indicated

Complete Blood Count

• First 3 months: Weekly to biweekly
• After month 3: Monthly

Additional Monitoring

• Blood pressure: Weekly for first 2 months, then monthly
• Renal function: Baseline and periodically
• Hepatic function: Baseline and periodically

Contraindications

Absolute Contraindications

• Hypersensitivity to niraparib or any excipient
• Pregnancy (Category D equivalent - can cause fetal harm)
• Breastfeeding

Relative Contraindications/Precautions

• Baseline platelet count <100,000/μL (high risk for severe thrombocytopenia) 4
• Active myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
• Severe renal impairment (not adequately studied)
• Severe hepatic impairment

Key Clinical Considerations

Risk Factors for Dose Interruption

Lower baseline platelet counts and lower nadir platelets during prior chemotherapy are significantly associated with increased thrombocytopenia risk 4. Patients with baseline platelets of 120 × 10⁹/L (interruption group) versus 215 × 10⁹/L (non-interruption group) showed markedly different outcomes.

Treatment Duration

• First-line maintenance: Continue for up to 3 years or until disease progression 2
• Recurrent disease: Continue until progression or unacceptable toxicity 1

Efficacy Maintained with Dose Reduction

Critically, dose reductions do not significantly impair progression-free survival 7. In the PRIMA trial, median PFS was 24.8 months with niraparib versus 8.3 months with placebo in the intention-to-treat population 8, and this benefit was maintained regardless of dose modifications 3.

Common Pitfall to Avoid

Real-world data shows that most patients who discontinued during their first episode of thrombocytopenia did not receive dose modifications prior to discontinuation 5. Always attempt dose reduction before discontinuing treatment, as 98% of thrombocytopenia cases resolve with appropriate management 5.

Long-term Safety

The risk of MDS/AML is 0.51 per 100 patient-years, and other second primary malignancies occur at 0.34 per 100 patient-years 9. These rates are consistent with clinical trial data and do not represent new safety signals.

Patient Selection

Niraparib is indicated regardless of BRCA mutation or homologous recombination deficiency (HRD) status 1, 2, though greatest benefit is seen in BRCA-mutated and HRD-positive patients 2, 8.